A New Collagen Peptide Review Enters a Fight Over Who's Paying for the Data

A new narrative review in Clinical, Cosmetic and Investigational Dermatology, published by Dove Medical Press, wades into one of dermatology's more contentious ongoing arguments: whether swallowing collagen peptides actually changes anything about your skin. The paper, authored by Dongyun Lei, Guoqiang Zhang, Tao Guo, Litao Zhang and Mao-Qiang Man of institutions including the Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital and the First Hospital of Hebei Medical University, surveyed PubMed and Google Scholar literature on human studies of oral collagen through October 2025.

It arrives roughly a year after a study that tried to settle the question and instead reignited it. A 2025 meta-analysis in the American Journal of Medicine, led by South Korean researchers pooling 23 randomized controlled trials and 1,474 participants, concluded there was "no clinical evidence to support the use of collagen supplements to prevent or treat skin aging." That headline obscured a more complicated result: the pooled data across all 23 trials actually showed significant improvements in hydration, elasticity and wrinkles. The null finding emerged only after the authors split studies by funding source and quality, finding that independently funded, higher-quality trials showed no effect while manufacturer-funded and lower-quality studies did.

That subgroup maneuver drew pushback. A published response in the journal's comments section and a white paper from Toslá Nutricosmetics, titled "Why the Latest Meta-Analysis on Collagen Misses the Mark," argued the funding-based split was methodologically shaky and buried a positive top-line result. Trade outlet NutraIngredients covered the backlash in August 2025, noting that regulators in Australia, South Korea, Canada, Japan and Brazil have already formally recognized skin-related collagen claims — a fact the supplement industry has leaned on to counter the "no evidence" framing.

The funding question keeps resurfacing in this literature. Studies backed by collagen manufacturers, or run by researchers affiliated with them, have tended to report more favorable skin outcomes than independently funded ones. A 2024 bioavailability study confirming that collagen-derived peptides show up in the bloodstream after ingestion was funded by Rousselot BV, one of the industry's largest gelatin and collagen producers — a small but telling data point on how closely funding and favorable results track in this field.

The mechanism researchers point to involves specific peptides — prolyl-hydroxyproline and hydroxyprolyl-glycine among them — that appear to survive digestion intact and turn up in blood at concentrations far higher than typical dietary peptides would predict, theoretically signaling skin cells to ramp up their own collagen and hyaluronic acid production. Critics, including a March 2026 piece from the American Council on Science and Health, counter that ingested collagen protein is still broken down like any other dietary protein for general metabolic use, and that detecting peptides in the blood doesn't prove they're doing anything specific for skin.

A bigger, newer synthesis complicates the picture further. In June 2026, researchers at Anglia Ruskin University published an umbrella review in Aesthetic Surgery Journal Open Forum covering 16 systematic reviews, 113 randomized trials and nearly 8,000 participants — the largest such analysis to date, as reported by ScienceDaily. It found real, if modest, benefits for skin and osteoarthritis symptoms with consistent long-term use, some benefit for muscle and tendon health, and essentially no benefit for athletic recovery or soreness, undercutting one of the supplement industry's other common marketing pitches.

Even where a benefit shows up, dermatologists have been cautioning against overselling it. A January 2026 ScienceDaily report quoted dermatologists warning that collagen supplements aren't the dramatic skin fix consumers have been led to expect from marketing copy. The stakes for getting the messaging right are considerable: the global collagen supplement market was estimated at somewhere between $1.9 billion and $4.8 billion in 2026, depending on how the category is scoped, with forecasts putting it near $9 billion by 2034.

The Dove Press review lands in the middle of that fight, built from a literature search that closes right where the American Journal of Medicine controversy was still unresolved and just months before the Anglia Ruskin umbrella review offered a more favorable, if narrower, verdict. Readers weighing its conclusions might reasonably start by checking the same thing critics have been asking about every other paper in this space: who paid for it.